These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26743640)

  • 1. MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Beauchemin P; Carruthers R
    Mult Scler; 2016 Feb; 22(2):254-6. PubMed ID: 26743640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J; Blanco Alonso R
    Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA).
    Kobayashi K; Okamoto Y; Inoue H; Usui T; Ihara M; Kawamata J; Miki Y; Mimori T; Tomimoto H; Takahashi R
    Intern Med; 2009; 48(15):1307-9. PubMed ID: 19652436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis.
    Palmou-Fontana N; Sánchez Gaviño JA; McGonagle D; García-Martinez E; Iñiguez de Onzoño Martín L
    Dermatology; 2014; 228(4):311-3. PubMed ID: 24942661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of infections in rheumatoid arthritis patients treated with tocilizumab.
    Lang VR; Englbrecht M; Rech J; Nüsslein H; Manger K; Schuch F; Tony HP; Fleck M; Manger B; Schett G; Zwerina J
    Rheumatology (Oxford); 2012 May; 51(5):852-7. PubMed ID: 21865281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
    Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
    Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.
    Matsumoto T; Nakamura I; Miura A; Momoyama G; Ito K
    Clin Rheumatol; 2013 Feb; 32(2):271-5. PubMed ID: 23149905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
    Zhang X; Peck R
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect?
    Wendling D; Dernis E; Prati C; Frisch E; Delbosc B
    J Rheumatol; 2011 Oct; 38(10):2284. PubMed ID: 21965707
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immunosuppression may mask severe infection. Septic arthritis in tocilizumab treatment yielded only modest acute-phase reaction].
    Ljung L; Smeds J; Persson G; Jirlén L; Toolanen G
    Lakartidningen; 2012 Sep 19-26; 109(38):1678-9. PubMed ID: 23094399
    [No Abstract]   [Full Text] [Related]  

  • 16. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
    Mitchell E; Jones G
    Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled--MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Comabella M
    Mult Scler; 2016 Feb; 22(2):257-8. PubMed ID: 26743639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents.
    Atzeni F; Talotta R; Masala IF; Gerardi MC; Casale R; Sarzi-Puttini P
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):500-510. PubMed ID: 31174819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report.
    Sato H; Kobayashi D; Abe A; Ito S; Ishikawa H; Nakazono K; Murasawa A; Kuroda T; Nakano M; Narita I
    BMC Res Notes; 2014 Sep; 7():641. PubMed ID: 25216562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.